March 22, 2022
The U.S. Food and Drug Administration today issued the guidance for industry, Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4. This guidance provides information to applicants and manufacturers of certain ophthalmic drugs packaged together with ophthalmic dispensers that the agency now intends to regulate these products as drug-led combination products.
FDA is issuing this guidance as a result of the District of Columbia Circuit Court’s decision in Genus Medical Technologies LLC v. U.S. Food and Drug Administration, where the court stated “[e]xcepting combination products, . . . devices must be regulated as devices and drugs --- if they do not also satisfy the device definition --- must be regulated as drugs.”
Before the Genus decision, the agency regulated ophthalmic dispensers as drugs when they were packaged together with ophthalmic drugs. However, in implementing Genus, the agency determined the ophthalmic dispensers meet the FD&C Act’s definition of a device and concluded that the language in 21 CFR 200.50(c) indicating that ophthalmic dispensers are regulated as drugs when packaged with ophthalmic drugs is obsolete. Therefore, FDA intends to regulate these products as drug-led combination products. Because the drug constituent part provides the primary mode of action, generally FDA’s Center for Drug Evaluation and Research will have primary jurisdiction over these products.
As a result of this change, these products are now subject to the applicable combination product current good manufacturing practice (CGMP) requirements and applicable combination product postmarketing safety reporting requirements. Therefore, we are issuing this guidance to communicate the agency’s compliance policy with respect to these products. Specifically, the guidance explains that
Additionally, the guidance describes FDA’s policy with respect to pending applications and how FDA will determine when compliance with the requirements of part 4, subpart A, must be demonstrated (i.e., during the review of the application or after approval).
See the guidance for more details.
October 22, 2015
On March 3, 2014, FDA announced a proposed rule that would amend the regulations regarding the labeling of conventional foods and dietary supplements. In this announcement, the Agency sought feedback...
January 7, 2016
Last month, the Agency released a proposed rule regarding FDA regulation of fixed-combination drugs. More specifically, the Agency is suggesting that its requirements for prescription...
April 18, 2016
On December 23, 2015, the FDA announced a proposed rule regarding the regulation of fixed-combination drugs. In its announcement, FDA proposed that its requirements for prescription fixed-combination...